Uncontrolled hypertension is directly associated with an increased risk of cardiovascular (CV) events and CV
disease. Hypertension has been a major health care concern for decades, and numerous clinical guidelines recommend
specific target blood pressure (BP) goals and evidence-based treatments. New data from outcomes studies continue to
evolve after the publication of hypertension treatment guidelines. Considering the current environment of rising health
care costs, managed care must continue to make decisions about how to best allocate resources for the management of
hypertension. This paper reviews current clinical practice guidelines in hypertension and highlights the role that the
angiotensin type II receptor blocker olmesartan medoxomil can play in the achievement and maintenance of
recommended BP goals.
Keywords: Blood pressure, clinical guidelines, goal BP, hypertension, managed care, olmesartan medoxomil, angiotensinogen, Olmesartan medoxomil.
Rights & PermissionsPrintExport